SCHEMBL4127534

SCHEMBL4127534

OC1CCCN(C2CCc3cc(-c4cncnc4)ccc3C2)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 7/20 0.46
CYP11B1 P15538 6/20 0.46
CYP1A2 P05177 4/20 0.46
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2B6 P20813 1/20 0.37
ROCK2 O75116 1/20 0.36
ROCK1 Q13464 1/20 0.36
CDC42BPB Q9Y5S2 1/20 0.36
KDM2B Q8NHM5 3/20 0.34
HRH3 Q9Y5N1 1/20 0.34
USP30 Q70CQ3 1/20 0.34
DRD2 P14416 1/20 0.33
FAAH O00519 1/20 0.32
DPP4 P27487 1/20 0.32
DPP8 Q6V1X1 1/20 0.32
DPP9 Q86TI2 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
SLC6A3 Q01959 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4131537 0.86 CYP11B1 (0.43) CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9
SCHEMBL4294921 0.81 USP30 (0.41) CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9
SCHEMBL4136604 0.80 KDM2B (0.42) CYP11B2CYP11B1CYP1A2KDM2BHRH3
SCHEMBL4136522 0.79 USP30 (0.46) CYP11B2KDM2BUSP30SLC6A2SLC6A4
SCHEMBL4149019 0.79 IRAK4 (0.48) CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9
SCHEMBL4128738 0.78 USP30 (0.36) CYP11B2CYP11B1CYP1A2KDM2BHRH3
SCHEMBL4135895 0.77 CYP11B1 (0.40) CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9
SCHEMBL4141043 0.77 KDM2B (0.38) CYP11B2CYP11B1CYP1A2KDM2BUSP30
SCHEMBL4147560 0.76 CYP11B1 (0.40) CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9
SCHEMBL4136231 0.75 HRH3 (0.45) KDM2BHRH3USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090163482-A1 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR MCHARDY STANTON FURST 2009-06-25 US claimed
EP-2007749-A2 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR Pfizer Products Inc. (US) 2008-12-31 EP claimed
WO-2007105053-A2 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR PFIZER PRODUCTS INC. (US) 2007-09-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163482-A1 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR HRH3, HRH4, HRH1 CYP11B2 745/4885CYP11B1 810/4885CYP1A2 1220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.